96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

An observational study on long‐term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate

“…In that study, eGFR decline was statistically significant comparing baseline to the first year, but at year 2 compared to year 1, eGFR decline was not statistically significant. Although this finding did not occur precisely in our study, the reduction in eGFR in our results tends to occur early in the treatment of TDF, as well as in other studies . These results may suggest that renal function should be monitored carefully during the initial 2 years of TDF therapy.…”

“…Although the follow‐up duration is short, based on these results, in the real world, TDF was widely used even in patients with decreased renal function until the development of tenofovir alafenamide fumarate (TAF). However, several recent studies suggested that TDF can reduce eGFR in patients with CHB, but long‐term real world data are still lacking.…”

“…However, the long‐term safety on renal function of TDF users for CHB is still unclear because of relatively recent approval of TDF use for CHB treatment in 2008 . Several previous studies reported that the effect of TDF on renal function is minimal, while other recent studies suggested that renal function was reduced after TDF use . Real world data of long‐term TDF use in Asia have been lacking .…”

Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepatitis B patients

“…However, the results suggested that FGF23 as a regulatory hormone of phosphorus metabolism increased first, before a serum phosphorus level increase was evident. This study suggested for the first time the possible effects of ETV on the renal tubules, similar tenofovir disoproxil fumarate, and suggested that measurement of urinary L‐FABP and serum FGF23 may be useful as early indicators of early tubular dysfunction‐induced changes in phosphorus metabolism during the administration of nucleoside/nucleotide analog drugs for the treatment of chronic hepatitis B.…”

Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy

“…In general, entecavir has excellent safety data on long‐term use . TAF has also improved the safety of TDF by reducing the risk of renal impairment and bone loss . Nonetheless, there are still a few challenges remained in the era of NA treatment.…”